Biocure Technology ROIC

Que fait Biocure Technology ? Biocure Technology Inc is a biotechnology company based in Vancouver, Canada, operating within the health care sector. The company went public on March 27, 2008, with the ticker CURE.X.CN and ISIN CA09075T2065. Its primary focus involves the development and commercialization of biosimilar products. Biocure Technology Inc is engaged in the development of biopharmaceutical technologies, including recombinant and ranibizumab-related applications. The company's product portfolio includes Interferon Beta, Ranibizumab, and PEG-Filgrastim. While the source description mentions CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers, this information is not confirmed by the provided facts and is excluded. Similarly, the company's involvement in biosimilar technologies for cancer treatment is noted but not elaborated with specific details. Biocure Technology Inc's website is https://biocuretech.com/, where further information can be found. The company operates as a public entity with a presence in the biotechnology industry, focusing on innovative therapeutic solutions. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are provided in the available information. Biocure Technology est l'une des entreprises les plus populaires sur Eulerpool.